What new treatments for Waldenstrom Macroglobulinemia are being developed in 2026

New and Emerging Treatments for Waldenstrom Macroglobulinemia in 2026

Based on the most current NCCN Guidelines (Version 1.2026), I can share what's on the horizon for WM treatment, though I should note that the guidelines focus primarily on established therapies rather than speculative future developments.

Current Treatment Landscape (2025-2026)

According to the NCCN Guidelines Version 1.2026, the field is actively evolving with several categories of treatments now available or in advanced development:

BTK Inhibitors (Bruton's Tyrosine Kinase Inhibitors)

These targeted therapies continue to be refined:

• Ibrutinib - established first-line option
• Zanubrutinib - another BTK inhibitor option
• Pirtobrutinib - a newer, reversible (non-covalent) BTK inhibitor showing promise in relapsed/refractory WM from the Phase 1/2 BRUIN study

The advantage of pirtobrutinib is that it's designed to be reversible, meaning it binds differently to BTK than earlier inhibitors, which may offer benefits for certain patients.

Proteasome Inhibitors

• Carfilzomib - offers a "neuropathy-sparing approach" (meaning it's less likely to cause nerve damage) when combined with rituximab and dexamethasone
• Ixazomib - an oral proteasome inhibitor showing long-term benefit in treatment-naive patients

BCL2 Antagonists

• Venetoclax - approved for previously treated WM, representing a newer class of targeted therapy that works by triggering cancer cell death through a different mechanism

What's Being Studied

The NCCN Guidelines note that several approaches are "ideally undertaken in the context of a clinical trial," suggesting active research in:

• Combination regimens with newer agents
• Strategies to overcome drug resistance
• Approaches to manage specific complications like peripheral neuropathy

Important Context About WM Treatment Development

According to NCCN Guidelines, treatment decisions for WM are increasingly personalized based on:

• MYD88 mutation status - present in most WM patients
• CXCR4 mutation status - affects response to BTK inhibitors (present in about 40% of patients)
• Disease burden and symptoms - determining whether "watch and wait" or immediate treatment is appropriate

Where to Find Information About Emerging Trials

If you're interested in clinical trials testing newer combinations or approaches:

• National Cancer Institute: cancer.gov/about-cancer/treatment/clinical-trials/search
• ClinicalTrials.gov: clinicaltrials.gov
• NCCN Cancer Centers: NCCN.org/cancercenters

Questions to Ask Your Care Team

If you're considering treatment options in 2026:

1. "Are there any clinical trials available for my specific WM profile (including my MYD88 and CXCR4 mutation status)?"

2. "Which of the newer BTK inhibitors or other targeted therapies would be most appropriate for my situation, and why?"

3. "What are the latest treatment combinations being studied, and would any be suitable for me?"

4. "If I develop resistance to my current treatment, what newer options would be available?"

5. "Are there trials specifically designed to reduce side effects like peripheral neuropathy?"

---

Important Note: The NCCN Guidelines emphasize that WM is a rare disease requiring specialized expertise. The most current treatment information and access to emerging therapies is typically available through NCCN-affiliated cancer centers or specialists experienced in WM care. The International Waldenstrom's Macroglobulinemia Foundation (IWMF.com) maintains a directory of WM specialists who stay current with the latest developments.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions about which treatments may be appropriate for your specific situation.